Tempus AI Reports Strong Q1 Revenue Growth, Improved EBITDA, and Raises Full-Year Guidance

summarizeSummary

Tempus AI reported strong first-quarter 2026 financial results, including a 36.1% year-over-year revenue increase and a significant improvement in Adjusted EBITDA, leading to raised full-year revenue guidance.

check_boxKey Events

• Strong Q1 Revenue Growth

  Revenue increased 36.1% year-over-year to $348.1 million, driven by 34.7% growth in Diagnostics revenue and 40.5% growth in Data and Applications revenue.

• Significant Adjusted EBITDA Improvement

  Adjusted EBITDA improved substantially from a loss of $16.2 million in Q1 2025 to a loss of $2.8 million in Q1 2026, indicating progress towards profitability.

• Raised Full-Year Revenue Guidance

  The company increased its full-year 2026 revenue guidance to a range of $1.59 billion to $1.60 billion, representing approximately 25% annual growth.

• Key Strategic Collaborations and Milestones

  Tempus AI announced new multi-year strategic collaborations with Merck, Gilead, Northwestern Medicine, and NYU Langone Health, alongside positive study results for its AI-driven diagnostic platforms.

auto_awesomeAnalysis

Tempus AI's first-quarter results demonstrate robust operational performance, with significant revenue growth and a substantial improvement in Adjusted EBITDA, nearing profitability. The company's decision to raise its full-year revenue guidance signals confidence in continued momentum. This positive financial update provides a strong counterpoint to recent insider selling activity, suggesting that the company's underlying business fundamentals are strengthening. Investors should monitor the continued execution of strategic collaborations and the path to sustained profitability.